Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfluorohexyloctane for Lid Wiper Epitheliopathy
NCT06671041Phase 4Completed
- Sponsor
- Southern College of Optometry
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perfluorohexyloctane in Lid wiper epitheliopathy (LWE) and dry eye disease (DED), sponsored by Southern College of Optometry. Primary endpoint: Visual Analog Scale at 2 months. Started May 2024; status: completed.
02
Drugs
perfluorohexyloctane
03
Conditions
Lid wiper epitheliopathy (LWE)dry eye disease (DED)
Beyond the preview
Go deeper on NCT06671041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671041.